Karyopharm Therapeutics Inc

NASDAQ:KPTI   3:59:58 PM EDT
5.65
+0.25 (+4.63%)
Earnings Announcements

Karyopharm Reports First Quarter 2022 Financial Results

Published: 05/05/2022 11:37 GMT
Karyopharm Therapeutics Inc (KPTI) - Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress.
Q1 Revenue Rose 105 Percent to $47.7 Million.
Q1 Loss per Share $0.53.
Karyopharm-expects Cash, Cash Equivalents & Investments, Expected Xpovio Revenue, License Agreements Revenue, Enough to Fund Planned Operations Into Early 2024.
Revenue is expected to be $35.96 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $39.35 Million
Next Quarter EPS Guidance is expected to be -$0.56

More details on our Analysts Page.